These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1412613)

  • 1. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
    Llerena A; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Jun; 14(3):261-4. PubMed ID: 1412613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
    Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
    Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.
    Salminen L; Lindberg R; Toivari HR; Huupponen R; Kaila T; Iisalo E
    Int Ophthalmol; 1989 Jan; 13(1-2):91-3. PubMed ID: 2787298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
    Wanwimolruk S; Chalcroft S
    Br J Clin Pharmacol; 1991 Nov; 32(5):617-20. PubMed ID: 1954076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
    Kallio J; Huupponen R; Pyykkö K
    Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW; Kong I; Cooper M; Sloan TP; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Aug; 16(2):157-66. PubMed ID: 6615690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic factors in the metabolism of haloperidol.
    Llerena A; Dahl ML; Ekqvist B; Bertilsson L
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():84A-85A. PubMed ID: 1499007
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
    Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
    Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.
    Llerena A; Cobaleda J; Martínez C; Benítez J
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):129-38. PubMed ID: 8839686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
    Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
    Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
    Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
    Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.